| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | DHP; DHPDHase; DPD; DPYD;;DHPDHase |
| WB Predicted band size | Calculated MW: 111 kDa ; Observed MW: 110 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human DHPDHase |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于DPYD抗体的假设性参考文献示例，供参考(请注意，这些内容为模拟生成，非真实存在的文献)：
---
1. **文献名称**：*Development of a Monoclonal Antibody for Sensitive Detection of DPYD in Colorectal Cancer Tissues*
**作者**：Smith A, et al.
**摘要**：本研究开发了一种高特异性的抗DPYD单克隆抗体，用于免疫组化检测结直肠癌患者组织中的DPYD蛋白表达。结果显示，DPYD低表达与5-氟尿嘧啶(5-FU)化疗的严重毒性反应显著相关，提示该抗体可作为个性化治疗的潜在生物标志物检测工具。
2. **文献名称**：*DPYD Antibody-Based ELISA for Predicting Fluoropyrimidine Toxicity*
**作者**：Johnson B, et al.
**摘要**：通过建立基于DPYD抗体的酶联免疫吸附试验(ELISA)，作者量化了患者血清中DPYD的浓度。研究发现，DPYD水平低于阈值的患者发生5-FU相关不良反应的风险显著升高，支持其在临床前毒性筛查中的应用。
3. **文献名称**：*Genetic Variants and DPYD Protein Expression: Correlation Studies Using Novel Antibody Probes*
**作者**：Lee C, et al.
**摘要**：利用新型多克隆抗体分析DPYD在不同人群中的表达水平，结合基因测序数据，揭示了DPYD基因突变(如*DPYD* rs3918290)与蛋白表达缺失的直接关联，为遗传性DPYD缺陷的快速诊断提供了依据。
4. **文献名称**：*Comparative Analysis of DPYD Detection Methods in Pancreatic Cancer*
**作者**：Garcia D, et al.
**摘要**：比较了免疫组化、Western blot及质谱法检测DPYD的效能，发现基于单克隆抗体的免疫组化法在临床样本中灵敏度最高。研究强调标准化DPYD抗体检测对优化化疗方案的重要性。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词(如“DPYD antibody detection”“DPYD fluoropyrimidine toxicity”)获取最新研究。
The DPYD antibody is a crucial tool in studying dihydropyrimidine dehydrogenase (DPD), an enzyme encoded by the DPYD gene. DPD plays a central role in pyrimidine metabolism, catalyzing the rate-limiting step in the degradation of thymine and uracil. Clinically, DPD is best known for its role in metabolizing the chemotherapeutic agent 5-fluorouracil (5-FU). Patients with DPYD deficiency, often due to genetic variants, experience severe toxicity from 5-FU, making DPD activity assessment vital for personalized oncology.
DPYD antibodies are widely used in research and diagnostics to detect DPD expression levels in tissues or cells. These antibodies enable techniques like immunohistochemistry (IHC), Western blotting, and ELISA, helping correlate enzyme abundance with functional activity. Monoclonal antibodies offer high specificity for quantitative assays, while polyclonal versions may detect multiple epitopes, useful in exploratory studies.
Structural studies using DPYD antibodies have revealed insights into DPD's homodimeric structure, cofactor binding domains, and post-translational modifications. Recent efforts focus on developing validated antibodies for clinical assays to pre-screen 5-FU candidates, though challenges remain in standardizing cross-platform reproducibility.
Emerging research also explores DPD's roles beyond chemotherapy metabolism, including its implications in neurological disorders and pyrimidine metabolism diseases. As precision medicine advances, DPYD antibodies remain essential for understanding DPD biology and optimizing therapeutic strategies.
×
